article Open AccessTop 1% cited

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

JNCI Journal of the National Cancer Institute · 2006 · Vol. 98(17) · pp. 1183–1192

Marc Buyse✉(International Drug Development Institute (Belgium))Sherene Loi(International Drug Development Institute (Belgium))Laura van’t Veer(International Drug Development Institute (Belgium))Giuseppe Viale(International Drug Development Institute (Belgium))Mauro Delorenzi(International Drug Development Institute (Belgium))Annuska M. Glas(European Institute of Oncology)Mahasti Saghatchian d'Assignies(European Institute of Oncology)Jonas Bergh(International Drug Development Institute (Belgium))Rosette Lidereau(International Drug Development Institute (Belgium))Peter Ellis(European Institute of Oncology)Adrian L. Harris(International Drug Development Institute (Belgium))Jan Bogaerts(International Drug Development Institute (Belgium))Patrick Therasse(European Institute of Oncology)Arno Floore(European Institute of Oncology)Mohamed Amakrane(International Drug Development Institute (Belgium))Fanny Piette(European Institute of Oncology)Emiel J. Rutgers(International Drug Development Institute (Belgium))Christos Sotiriou(International Drug Development Institute (Belgium))Fátima Cardoso(European Institute of Oncology)Martine Piccart(European Institute of Oncology)

View via DOI Full-text PDF

Abstract

The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer.

Breast Cancer Treatment Studies Cancer Genomics and Diagnostics HER2/EGFR in Cancer ResearchHazard ratioBreast cancerOncologyMedicineInternal medicineGene signatureProportional hazards modelConfidence intervalCancerGene

MeSH terms

AdultBreast NeoplasmsEuropeFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPredictive Value of TestsPrognosisRisk FactorsROC CurveSensitivity and SpecificityBiomarkers, Tumor

Citations

1,223

FWCI

43.92

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers